Mersana Therapeutics (MRSN)
(Delayed Data from NSDQ)
$9.88 USD
-0.66 (-6.22%)
Updated Oct 17, 2025 04:00 PM ET
After-Market: $9.94 +0.06 (0.61%) 7:58 PM ET
3-Hold of 5 3
C Value D Growth B Momentum D VGM
Fundamental Charts
About PEG Ratio (TTM)
The company's trailing twelve month (TTM) PEG ratio is the P/E ratio divided by its long-term growth rate consensus. This ratio essentially compares the P/E to its growth rate, thus, for many, telling a more complete story than just the P/E ratio alone. Conventional wisdom says that a PEG ratio of 1 or less is considered good (at par or undervalued to its growth rate). A value greater than 1, in general, is not as good (overvalued to its growth rate). For example, a company with a P/E ratio of 25 and a growth rate of 20% would have a PEG ratio of 1.25 (25 / 20 = 1.25). A company with a P/E ratio of 40 and a growth rate of 50% would have a PEG ratio of 0.80 (40 / 50 = 0.80). Traditionally, investors would look at the stock with the lower P/E and deem it a bargain. But when compared to its growth rate, it doesn't have the earnings growth to justify its P/E. In this example, the one with the P/E of 40 is the better bargain because it is selling at a discount to its growth rate. So the PEG ratio tells you what you're paying for each unit of earnings growth.
MRSN 9.88 -0.66(-6.22%)
Will MRSN be a Portfolio Killer in October?
Zacks Investment Research is releasing its prediction for MRSN based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for MRSN
Wall Street Analysts See a 314.81% Upside in Mersana Therapeutics (MRSN): Can the Stock Really Move This High?
Wall Street Analysts Think Mersana Therapeutics (MRSN) Could Surge 248.83%: Read This Before Placing a Bet
MRSN: What are Zacks experts saying now?
Zacks Private Portfolio Services
Mersana Therapeutics, Inc. (MRSN) Reports Q2 Loss, Lags Revenue Estimates
Stoke Therapeutics, Inc. (STOK) Reports Q2 Loss, Tops Revenue Estimates
VistaGen Therapeutics, Inc. (VTGN) Reports Q1 Loss, Misses Revenue Estimates
Other News for MRSN
Is MRSN poised for a decline? 200 Day Moving Average Resistance shows up after crashing 6.22%
200 Day Moving Average Resistance appears for MRSN after 0.05% move
Is MRSN likely to continue higher? Pocket Pivot shows up after advancing 2.23%
Upper Bollinger Band Walk appears for MRSN after 3.94% move
Is MRSN poised for gains? New Uptrend shows up after rallying 7.25%